Sunitinib and sorafenib in patients with metastatic renal cell cancer: access and performance in Uruguay
In Uruguay, renal cell cancer (RCC) is the nineth and eleventh in frequency in men and woman, respectively. Sunitinib and Sorafenib inhibits receptor of vascular endothelial and platelet-derived, growth factor. Both are funded, with centrally and universal coverage, for metastatic RCC patients. The coverage include first-line treatment in patients without significant chance of benefit of treatment with IL-2 or I-α, and, second-line in patients without response to IL-2 or I-α. A regulatory framework for coverage and a systematic process of evaluation were established. Objective: Assess the access, effectiveness and tolerance of Sunitinib and Sorafenib in metastatic RCC.
Autores:
Lic. Marcela Baldizzoni, QF. Silvia Perez, Dr. Henry Albornoz, Dr. Fernando Correa. Lic. Marcela Baldizzoni, QF. Silvia Perez, Dr. Henry Albornoz, Dr. Fernando Correa.
Tipo de publicación:
P. CIENTÍFICAS - Póster y Presentaciones